Clinical Trial TitleStudy Evaluating the Safety and Efficacy of Semaglutide, and the Fixed-Dose Combination of Cilofexor and Firsocostat, Alone and in Combination, in Subjects with Compensated Cirrhosis (F4) due to Nonalcoholic Steatohepatitis (NASH)
National Clinical Trial Number:NCT04971785
Clinical Trial Protocol Description:
This phase 2, randomized, double-blind, double-dummy, placebo-controlled study is looking at the safety and efficacy of semaglutide and the fixed-dose combination of cilofexor and firsocostat, alone and in combination, in individuals with NASH and associated cirrhosis. There is a placebo group as well in this study.
Clinical Trial Eligibility Criteria:
In order to participate you must meet the following criteria:
- Have cirrhosis due to NASH as seen on a liver biopsy.
- Have a platelet count greater than or equal to 125,000/uL.
- Not have type 1 diabetes.
- Not be taking a diabetic medication from the GLP-1 drug class.
This is a partial list of eligibility requirements. To inquire about your eligibility, please call the contact number provided. If you wish to inquire via email, please include the title of the study in your message.